Evaluating the effectiveness of anti-Nogo treatment in spinal cord injuries

Neural Development, 2020 · DOI: https://doi.org/10.1186/s13064-020-0138-9 · Published: January 5, 2020

Spinal Cord Injury Pharmacology Regenerative Medicine

Simple Explanation

Spinal cord injuries (SCI) lead to permanent damage due to the inability of the central nervous system (CNS) to regenerate axons, resulting in loss of sensory and motor function. One major inhibitory signal in the CNS is the Nogo pathway, which prevents neurite outgrowth. Anti-Nogo antibodies can target this pathway, promoting axon regeneration and improving sensory and motor function. The review evaluates the potential of anti-Nogo treatment in clinical settings for SCI and discusses methods to improve the treatment while addressing developmental obstacles.

Study Duration

Not specified

Participants

Rats and primates

Evidence Level

Not specified

Key Findings

1
Anti-Nogo antibodies have consistently demonstrated improvement in motor function recovery in rats and primates, including fine finger control.
2
Treatment with anti-Nogo antibodies has shown promise in alleviating other symptoms of SCI such as bladder dysfunction and muscle spasms.
3
The mechanism of action involves increased sprouting and bypass pathways in supraspinal and intraspinal circuitry, rather than axonal regeneration through the lesion site.

Research Summary

The Nogo pathway stabilizes CNS circuitry, limiting plasticity and functional recovery after spinal cord damage. Anti-Nogo antibodies improve anatomical and functional recovery, particularly with acute treatment and subsequent dexterity training, enhancing supraspinal and intraspinal bypass pathways. Further research is needed to understand Nogo pathway interactions, recovery mechanisms, and to address potential cortical side effects, such as impacts on memory and behavior.

Practical Implications

Clinical Application

Anti-Nogo antibody treatment shows potential for improving motor function and alleviating associated symptoms of SCI in clinical settings.

Therapeutic Strategies

Combining anti-Nogo therapy with dexterity training and other interventions, such as cell grafts or glial scar inhibition, may enhance functional recovery.

Further Research

Further investigation into the Nogo pathway, recovery mechanisms, and potential side effects is crucial for optimizing treatment strategies and ensuring patient safety.

Study Limitations

1
Genetic evidence supporting the efficacy of anti-Nogo treatment is mixed.
2
Increased plasticity alone may not guarantee improved outcomes; appropriate connection selection and maintenance are necessary.
3
Inhibition of the Nogo pathway could have negative effects in the cortex, potentially leading to behavioral changes or other complications.

Your Feedback

Was this summary helpful?

Back to Spinal Cord Injury